Corvus Pharmaceuticals prices $22.15/share public offering of ~9.1M shares for ~$188.3M net proceeds

Corvus Pharmaceuticals, Inc.

Upsized public offering of 7,900,677 shares at $22.15/share; underwriters fully exercised 30-day option for 1,185,101 additional shares.
Expected net proceeds of approximately $188.3 million after underwriting discounts and expenses.
Net proceeds to fund working capital and R&D for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma trials.
Offering expected to close on January 23, 2026; Jefferies and Goldman Sachs acted as lead underwriters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.